• Je něco špatně v tomto záznamu ?

Pregn-5-en-3beta-ol and androst-5-en-3beta-ol dicarboxylic acid esters as potential therapeutics for NMDA hypofunction: In vitro safety assessment and plasma stability

M Matousova, R Soucek, E Tloustova, B Slavikova, H Chodounska, H Mertlikova-Kaiserova, E Kudova

. 2019 ; (147) : 4-9.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc20017140

Grantová podpora
NV15-29370A MZ0 CEP - Centrální evidence projektů

Neurosteroids are endogenous steroidal compounds that can modulate neuronal receptors. N-Methyl-D-aspartate receptors (NMDARs) are glutamate-gated, calcium-permeable ion channels that are of particular interest, as they participate in synaptic transmission and are implicated in various processes, such as learning, memory, or long-term neuronal potentiation. Positive allosteric modulators that increase the activity of NMDARs may provide a therapeutic aid for patients suffering from neuropsychiatric disorders where NMDAR hypofunction is thought to be involved, such as intellectual disability, autism spectrum disorder, or schizophrenia. We recently described a new class of pregn-5-ene and androst-5-ene 3beta-dicarboxylic acid hemiesters (2-24) as potent positive modulators of NMDARs. Considering the recommended guidelines for the early stage development of new, potent compounds, we conducted an in vitro safety assessment and plasma stability screening to evaluate their druglikeness. First, compounds were screened for their hepatotoxicity and mitochondrial toxicity in a HepG2 cell line. Second, toxicity in primary rat postnatal neurons was estimated. Next, the ability of compounds 2-24 to cross a Caco-2 monolayer was also studied. Finally, rat and human plasma stability screening revealed an unforeseen high stability of the C-3 hemiester moiety. In summary, by using potency/efficacy towards NMDARs data along with toxicity profile, Caco-2 permeability and plasma stability, compounds 14 and 15 were selected for further in vivo animal studies. Copyright © 2018 Elsevier Inc. All rights reserved.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20017140
003      
CZ-PrNML
005      
20220411125043.0
007      
ta
008      
201031s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.steroids.2018.09.012 $2 doi
035    __
$a (PubMed)30296546
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Matousova, Marika $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nam. 2, Prague 6, Dejvice 16610, Czech Republic.
245    10
$a Pregn-5-en-3beta-ol and androst-5-en-3beta-ol dicarboxylic acid esters as potential therapeutics for NMDA hypofunction: In vitro safety assessment and plasma stability / $c M Matousova, R Soucek, E Tloustova, B Slavikova, H Chodounska, H Mertlikova-Kaiserova, E Kudova
520    9_
$a Neurosteroids are endogenous steroidal compounds that can modulate neuronal receptors. N-Methyl-D-aspartate receptors (NMDARs) are glutamate-gated, calcium-permeable ion channels that are of particular interest, as they participate in synaptic transmission and are implicated in various processes, such as learning, memory, or long-term neuronal potentiation. Positive allosteric modulators that increase the activity of NMDARs may provide a therapeutic aid for patients suffering from neuropsychiatric disorders where NMDAR hypofunction is thought to be involved, such as intellectual disability, autism spectrum disorder, or schizophrenia. We recently described a new class of pregn-5-ene and androst-5-ene 3beta-dicarboxylic acid hemiesters (2-24) as potent positive modulators of NMDARs. Considering the recommended guidelines for the early stage development of new, potent compounds, we conducted an in vitro safety assessment and plasma stability screening to evaluate their druglikeness. First, compounds were screened for their hepatotoxicity and mitochondrial toxicity in a HepG2 cell line. Second, toxicity in primary rat postnatal neurons was estimated. Next, the ability of compounds 2-24 to cross a Caco-2 monolayer was also studied. Finally, rat and human plasma stability screening revealed an unforeseen high stability of the C-3 hemiester moiety. In summary, by using potency/efficacy towards NMDARs data along with toxicity profile, Caco-2 permeability and plasma stability, compounds 14 and 15 were selected for further in vivo animal studies.<ovid:br/><ovid:br/> Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.
650    02
$a androstenoly $x chemie $x farmakologie $x krev $7 D000737
650    02
$a zvířata $7 D000818
650    02
$a poruchy autistického spektra $x farmakoterapie $x metabolismus $7 D000067877
650    02
$a viabilita buněk $x účinky léků $7 D002470
650    02
$a cholesterol $x chemie $x farmakologie $x krev $7 D002784
650    02
$a kyseliny dikarboxylové $x chemie $x farmakologie $x krev $7 D003998
650    02
$a stabilita léku $7 D004355
650    02
$a estery $x chemie $x farmakologie $x krev $7 D004952
650    02
$a buňky Hep G2 $7 D056945
650    02
$a lidé $7 D006801
650    02
$a Intellectual Disability $x dt [Drug Therapy]
650    02
$a Intellectual Disability $x me [Metabolism]
650    02
$a Mitochondria $x de [Drug Effects]
650    02
$a Mitochondria $x me [Metabolism]
650    02
$a Molecular Structure
650    02
$a Neurons $x de [Drug Effects]
650    02
$a Neurons $x me [Metabolism]
650    02
$a Neuroprotective Agents $x bl [Blood]
650    02
$a Neuroprotective Agents $x ch [Chemistry]
650    12
$a Neuroprotective Agents $x pd [Pharmacology]
650    12
$a Pregnenolone $x aa [Analogs & Derivatives]
650    02
$a Pregnenolone $x bl [Blood]
650    02
$a Pregnenolone $x pd [Pharmacology]
650    02
$a Rats
650    02
$a Rats, Wistar
650    12
$a Receptors, N-Methyl-D-Aspartate $x ai [Antagonists & Inhibitors]
650    02
$a Receptors, N-Methyl-D-Aspartate $x me [Metabolism]
650    02
$a Schizophrenia $x dt [Drug Therapy]
650    02
$a Schizophrenia $x me [Metabolism]
650    02
$a Tumor Cells, Cultured
700    1_
$a Soucek, Radko
700    1_
$a Tloušťová, Eva $7 xx0118948
700    1_
$a Slavíková, Barbora $7 xx0139129
700    1_
$a Chodounská, Hana $7 xx0168202
700    1_
$a Mertlíková-Kaiserová, Helena, $d 1979- $7 xx0121687
700    1_
$a Kudová, Eva $7 xx0233922
773    0_
$t Steroids $g č. 147 (2019), s. 4-9 $p Steroids $x 0039-128X $w MED00004438
773    0_
$p Steroids $g 147:4-9, 2019 07
910    __
$a ABA008 $y p $z 0
990    __
$a 20201031114513 $b ABA008
991    __
$a 20220411125041 $b ABA008
999    __
$a ok $b bmc $g 1577901 $s 1107326
BAS    __
$a 3
BMC    __
$a 2019 $c 147 $d 4-9 $x MED00004438 $i 0039-128X $m Steroids
GRA    __
$a NV15-29370A $p MZ0
LZP    __
$a 2020-lp

Najít záznam

Citační ukazatele

Možnosti archivace